When a thousand people worldwide suffered from lethal coronavirus (COVID-19) in 2020, we came up with an ambitious project to contribute to the worldwide pandemic solution.
Everything started with the question: How can we contribute as a small chemical company? Firstly, we thought about the distribution of anti-bacterial solutions, but this intention was unfortunately limited by Good manufacturing practice (GMP) for companies with a licence. Therefore, we turned out attention to the area that is closest to us and in which we excel, organic synthesis.
When the pandemic started, the hunt for an effective vaccine was launched simultaneously. Scientists from all over the world began their fight against a new type of coronavirus. First of all, the known potential drugs were re-purposed and tested. The most promising, which showed preliminary activity against COVID-19, were Remdesivir, Favipiravir, Chloroquine, Hydroxychloroquine, Azithromycin, etc. (Figure 1).
Figure 1: Structures of the most promising drug candidates for treating COVID-19.
Aviromix- antiviral drug candidate kit
We realized it was almost impossible to find a distributor that offers all of the most promising drug candidates for treating COVID-19. Moreover, the shipping times ranged from 1 to 4 weeks, which was unacceptable under this pandemic situation, where hundreds of people died every day.
Our goal was the distribution of antiviral sets consisting of the five most potent and promising re-purposed drugs in a short time. These sets were designed for institutes dealing with the synthesis of new promising drug candidates, virology labs, and microbiology labs to promote their effort. The significant advantages of this set were as follows:
1. quick delivery (within 48 h in EU)
2. all potential drugs at once, ready for use
3. extensive supporting information for each drug in the set
4. DNA free
5. easy to find on our new website
These sets (called Aviromix) may also serve as potential standards for the comparatition of newly invented drugs or as building blocks.
During only three months, starting from January 2020, we optimized the total multigram scaled synthesis of Remdesivir in our lab (Figure 2). The rest of the drug candidates were purchased, dosed into the sets and irradiated to destroy all present DNA. All the missing analytical information was completed, and if necessary further purification was undergone. We also created a new website for convenient and quick purchases for our future customers.
If you want to read more about our research of antiviral nucleoside prodrugs such as Remdesivir, you can find our article published previously here.
And what happened next?
Since we were already successful with the synthesis of Remdesivir, we turned our attention to Remdesivir metabolites, mono-, di- and triphosphate. To this day we have sold these Remdesivir phosphates to tens of clients worldwide.
Finally, with gaining experience in the field of antiviral compounds, we have advanced our research to the development of novel nucleoside triphosphates with biological activity. You can read more about this research here.
If you want to discover more about our services, discuss specific research, or receive a proposal, please do not hesitate to write an email to Krystof Sigut at firstname.lastname@example.org or reach him on the phone +420 776 750 591.
Drop us a line
We will respond as soon as possible, typically within 48 hours.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.